Pediatric Allergy, Immunology, and PulmonologyVol. 32, No. 2 https://doi.org/10.1089/ped.2018.0948
Mehmet Kilic, Sema Ecin, Erdal Taskin, Askin Sen, and Murat Kara
Overview Asthma and Vitamin D contains
- Atopies (allergy, asthma, rhinitis, etc.) variously associated with low Vitamin D and poor Vitamin D Receptor – Aug 2021
- Poor response to Asthma inhaler if poor Vitamin D Receptor – Dec 2019
- Asthma 3.7X higher risk of poor Vitamin D Receptor (teens in Taiwan in this case) – Nov 2019
- Asthma is 20 percent more likely with a poor Vitamin D Receptor gene – meta-analysis Oct 2019
- Asthmatic children 5X more likely to have a poor Vitamin D Receptor – June 2019
- Childhood asthma about 1.3 times more likely if poor Vitamin D Receptor – meta-analysis Aug 2016
- 2X higher risk of wheezing and asthma if modified receptor genes, even if vitamin D levels OK – Sept 2015
- This list is NOT automatically updated
The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019
Vitamin D Receptor Activation can be increased by any of:
Resveratrol, Omega-3, Magnesium, Zinc, non-daily Vitamin D dosing, etc
Note: The founder of VitaminDWiki uses 10 of the 12 known VDR activators
Note: Unknown if Asthma ==>Poor VDR or if Poor VDR ==> Asthma
Note: Inhaling Vitamin D is looking promising for various breathing problems as of mid 2019
Background: The association between vitamin D receptor (VDR) polymorphisms and the risk of asthma remains unclear. This study aimed to investigate the effect of VDR gene polymorphisms and VDR mRNA expression levels on respiratory function, nitric oxide levels in expiratory air, and serum vitamin D levels in children with asthma.
Materials and Methods: The study included 80 healthy children (control group) and 100 asthmatic children (asthma group) between the age of 5 and 18 years. The VDR genotypes (ApaI, TaqI, and FokI) and VDR mRNA levels were determined in all groups.
Results: There was no statistically significant difference in vitamin D levels between the asthma group and the control group (P > 0.05). A significant association was found between both
- genotype (CC) of the TaqI polymorphism [odds ratio (OR) = 0.2, 95% confidence interval (CI) (0.07–0.5), P = 0.003] and
- genotype (CA) of ApaI polymorphisms [OR = 0.2, 95% CI (0.07–0.8), P = 0.02], and asthma risk.
In addition, when single-nucleotide polymorphism allelic frequencies between asthma and control groups were compared there is no significant association (P > 0.05). When compared to control group, VDR mRNA expression in asthma group decreased in genotypes CC and CA of ApaI and in genotypes TT and TC of TaqI (P < 0.05).
Conclusion: The results provide supporting evidence for an association between TaqI and ApaI polymorphisms and asthma susceptibility.